Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Maxigen Biotech Inc. (1783:TWSE), powered by AI.
Maxigen Biotech Inc. is currently trading at $38.55. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Maxigen Biotech Inc. on Alpha Lenz.
View Maxigen Biotech Inc.'s valuation metrics on Alpha Lenz.
“Maxigen Biotech Inc.'s ROE is 18.2%. Explore profitability and growth together.”
Ask for details →Maxigen Biotech Inc. is a biotechnology company dedicated to the research, development, and commercialization of health and beauty products. Its primary focus is on producing innovative biomedical and cosmeceutical products that integrate both scientific and cosmetic benefits. The company's product portfolio includes pharmaceuticals, dietary supplements, skincare products, and functional cosmetics, all benefiting from its proprietary biotechnology advancements. Maxigen Biotech Inc. plays a significant role in the health and beauty industry by combining cutting-edge biotechnological research with consumer-focused applications. It serves diverse sectors, from healthcare and wellness to cosmetics, addressing consumer needs for effective and safe products with scientifically-backed efficacy. The company utilizes state-of-the-art laboratory processes to ensure the highest standards of product quality and performance. In the financial market, Maxigen Biotech Inc. represents an intersection of technology and consumer goods, offering investors insight into emerging trends in biotechnology and personal care. Its innovative approaches and commitment to integrating science with everyday products enhance its relevance and influence in both the biotech sphere and the wider consumer marketplace.
“Maxigen Biotech Inc.'s ROE is 18.2%. Explore profitability and growth together.”
Ask for details →Maxigen Biotech Inc. (ticker: 1783) is a company listed on TWSE in the Healthcare sector (Medical Instruments & Supplies).
The current price is 38.55 with a P/E ratio of -x and P/B of -x.
ROE is 18.22% and operating margin is 31.26%. Annual revenue is $812M.